Recombinant Human TNFRSF17 protein (rFc Tag)
种属
Human
纯度
>90 %, SDS-PAGE
标签
rFc Tag
生物活性
未测试
验证数据展示
产品信息
纯度 | >90 %, SDS-PAGE |
内毒素 | <1.0 EU/μg protein, LAL method |
生物活性 |
Not tested |
来源 | HEK293-derived Human TNFRSF17 protein Met1-Ala54 (Accession# Q02223) with a rabbit IgG Fc tag at the C-terminus. |
基因ID | 608 |
蛋白编号 | Q02223 |
预测分子量 | 32.2 kDa |
SDS-PAGE | |
组分 | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
复溶 | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
储存条件 |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
背景信息
BCMA (B cell maturation antigen), also known as TNFRSF17, is 20.2-kDa type III transmembrane glycoprotein and is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes and plasma cells, which may be important for B cell development and autoimmune response. BCMA has two agonist ligands: a proliferation-inducing ligand (APRIL) and BAFF. When BCMA binds to APRIL, it transmits signals of cell survival and proliferation; when BCMA binds to BAFF, it mediates the activation of NF-kappaB and MAPK8/JNK. It has been found that the overexpression and activation of BCMA are associated with multiple myeloma (MM) in preclinical models and humans, supporting its potential utility as a therapeutic target for MM.
参考文献:
1. Bo Yu et al (2020). J Hematol Oncol. Sep 17;13(1):125. 2. C Madry et al (1998). Int Immunol. Nov;10(11):1693-702. 3. Yu-Tzu Tai et al (2016). Blood. Jun 23;127(25):3225-36. 4. Fabrice Jardin (2022). Biomedicines. Sep 1;10(9):2153. 5. Nina Shah et al (2020). Leukemia. Apr;34(4):985-1005.